Skip to main content
Atrás
SGIOF logo

Shionogi & Co., Ltd.

Calidad de datos: 100%
SGIOF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$21.45
▲ $3.45 (19.17%)
Cap. Mercado: 18.25B
También listada como SGIOY OTC
Rango del Día
$21.45 $21.45
Rango de 52 Semanas
$14.25 $26.00
Volumen
471
Promedio 50D / 200D
$21.12 / $17.96
Cierre Anterior
$18.00

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 0.1 0.3
P/B 0.0 2.9
ROE % 13.1 3.7
Net Margin % 38.9 3.8
Rev Growth 5Y % 10.2 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $263.73
$220.71 – $286.42
 730 B 2
FY2029 $276.54
$231.43 – $300.33
 740 B 4
FY2028 $288.94
$241.82 – $313.80
 700 B 3

Puntos Clave

Revenue grew 10.20% annually over 5 years — strong growth
ROE of 13.12% — decent returns on equity
Net margin of 38.89% shows strong profitability
Debt/Equity of 0.02 — conservative balance sheet
Generating 143.36B in free cash flow
P/E of 0.11 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
10.20%
Revenue (1Y)0.73%
Earnings (1Y)5.19%
FCF Growth (3Y)0.95%

Calidad

Return on Equity
13.12%
ROIC8.49%
Net Margin38.89%
Op. Margin35.73%

Seguridad

Debt / Equity
0.02
Current Ratio6.63
Interest Coverage17.35

Valoración

P/E Ratio
0.11
P/B Ratio0.01
EV/EBITDA-2.14
Dividend Yield0.07%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.73% Revenue Growth (3Y) 1.35%
Earnings Growth (1Y) 5.19% Earnings Growth (3Y) -4.01%
Revenue Growth (5Y) 10.20% Earnings Growth (5Y) 11.10%
Profitability
Revenue (TTM) 438.27B Net Income (TTM) 170.44B
ROE 13.12% ROA 11.10%
Gross Margin 85.44% Operating Margin 35.73%
Net Margin 38.89% Free Cash Flow (TTM) 143.36B
ROIC 8.49% FCF Growth (3Y) 0.95%
Safety
Debt / Equity 0.02 Current Ratio 6.63
Interest Coverage 17.35 Dividend Yield 0.07%
Valuation
P/E Ratio 0.11 P/B Ratio 0.01
P/S Ratio 0.04 PEG Ratio 0.50
EV/EBITDA -2.14 Dividend Yield 0.07%
Market Cap 18.25B Enterprise Value -334.66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 438.27B 435.08B 426.68B 335.14B 297.18B
Net Income 170.44B 162.03B 184.97B 114.19B 111.86B
EPS (Diluted) 600.98 558.32 621.09 378.62 364.89
Gross Profit 374.44B 377.48B 364.44B 279.72B 244.65B
Operating Income 156.60B 153.31B 149.00B 110.31B 117.44B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.54T 1.42T 1.31T 1.15T 998.99B
Total Liabilities 172.85B 164.36B 189.92B 157.32B 134.44B
Shareholders' Equity 1.36T 1.24T 1.10T 975.66B 846.11B
Total Debt 21.88B 11.62B 9.41B 6.67B 7.99B
Cash & Equivalents 374.80B 358.09B 309.22B 254.42B 276.17B
Current Assets 858.50B 784.21B 784.19B 659.21B 556.24B
Current Liabilities 129.39B 133.91B 158.55B 124.40B 100.18B

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#497 of 827
37
Value Defensive Investing (Benjamin Graham)
#636 of 709
4

Actividad Reciente

Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026